Literature DB >> 27587634

Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection.

Robert W Cross1, Matthew L Boisen2, Molly M Millett3, Diana S Nelson4, Darin Oottamasathien3, Jessica N Hartnett5, Abigal B Jones3, Augustine Goba6, Mambu Momoh7, Mohamed Fullah7, Zachary A Bornholdt8, Marnie L Fusco8, Dafna M Abelson8, Shunichiro Oda8, Bethany L Brown3, Ha Pham3, Megan M Rowland9, Krystle N Agans1, Joan B Geisbert1, Megan L Heinrich9, Peter C Kulakosky10, Jeffrey G Shaffer11, John S Schieffelin12, Brima Kargbo13, Momoh Gbetuwa6, Sahr M Gevao14, Russell B Wilson10, Erica Ollmann Saphire8, Kelly R Pitts3, Sheik Humarr Khan6, Donald S Grant6, Thomas W Geisbert1, Luis M Branco9, Robert F Garry15.   

Abstract

BACKGROUND: Ebola virus disease (EVD) is a severe viral illness caused by Ebola virus (EBOV). The 2013-2016 EVD outbreak in West Africa is the largest recorded, with >11 000 deaths. Development of the ReEBOV Antigen Rapid Test (ReEBOV RDT) was expedited to provide a point-of-care test for suspected EVD cases.
METHODS: Recombinant EBOV viral protein 40 antigen was used to derive polyclonal antibodies for RDT and enzyme-linked immunosorbent assay development. ReEBOV RDT limits of detection (LOD), specificity, and interference were analytically validated on the basis of Food and Drug Administration (FDA) guidance.
RESULTS: The ReEBOV RDT specificity estimate was 95% for donor serum panels and 97% for donor whole-blood specimens. The RDT demonstrated sensitivity to 3 species of Ebolavirus (Zaire ebolavirus, Sudan ebolavirus, and Bundibugyo ebolavirus) associated with human disease, with no cross-reactivity by pathogens associated with non-EBOV febrile illness, including malaria parasites. Interference testing exhibited no reactivity by medications in common use. The LOD for antigen was 4.7 ng/test in serum and 9.4 ng/test in whole blood. Quantitative reverse transcription-polymerase chain reaction testing of nonhuman primate samples determined the range to be equivalent to 3.0 × 105-9.0 × 108 genomes/mL.
CONCLUSIONS: The analytical validation presented here contributed to the ReEBOV RDT being the first antigen-based assay to receive FDA and World Health Organization emergency use authorization for this EVD outbreak, in February 2015.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  Ebola, point of care; diagnostic; lateral flow immunoassay

Mesh:

Substances:

Year:  2016        PMID: 27587634      PMCID: PMC5050482          DOI: 10.1093/infdis/jiw293

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus.

Authors:  Kristian G Andersen; B Jesse Shapiro; Christian B Matranga; Rachel Sealfon; Aaron E Lin; Lina M Moses; Onikepe A Folarin; Augustine Goba; Ikponmwonsa Odia; Philomena E Ehiane; Mambu Momoh; Eleina M England; Sarah Winnicki; Luis M Branco; Stephen K Gire; Eric Phelan; Ridhi Tariyal; Ryan Tewhey; Omowunmi Omoniwa; Mohammed Fullah; Richard Fonnie; Mbalu Fonnie; Lansana Kanneh; Simbirie Jalloh; Michael Gbakie; Sidiki Saffa; Kandeh Karbo; Adrianne D Gladden; James Qu; Matthew Stremlau; Mahan Nekoui; Hilary K Finucane; Shervin Tabrizi; Joseph J Vitti; Bruce Birren; Michael Fitzgerald; Caryn McCowan; Andrea Ireland; Aaron M Berlin; James Bochicchio; Barbara Tazon-Vega; Niall J Lennon; Elizabeth M Ryan; Zach Bjornson; Danny A Milner; Amanda K Lukens; Nisha Broodie; Megan Rowland; Megan Heinrich; Marjan Akdag; John S Schieffelin; Danielle Levy; Henry Akpan; Daniel G Bausch; Kathleen Rubins; Joseph B McCormick; Eric S Lander; Stephan Günther; Lisa Hensley; Sylvanus Okogbenin; Stephen F Schaffner; Peter O Okokhere; S Humarr Khan; Donald S Grant; George O Akpede; Danny A Asogun; Andreas Gnirke; Joshua Z Levin; Christian T Happi; Robert F Garry; Pardis C Sabeti
Journal:  Cell       Date:  2015-08-13       Impact factor: 41.582

2.  Clinical virology of Lassa fever in hospitalized patients.

Authors:  K M Johnson; J B McCormick; P A Webb; E S Smith; L H Elliott; I J King
Journal:  J Infect Dis       Date:  1987-03       Impact factor: 5.226

Review 3.  Ebola haemorrhagic fever.

Authors:  Heinz Feldmann; Thomas W Geisbert
Journal:  Lancet       Date:  2011-03-05       Impact factor: 79.321

4.  Assembly of the Ebola Virus Nucleoprotein from a Chaperoned VP35 Complex.

Authors:  Robert N Kirchdoerfer; Dafna M Abelson; Sheng Li; Malcolm R Wood; Erica Ollmann Saphire
Journal:  Cell Rep       Date:  2015-06-25       Impact factor: 9.423

5.  ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study.

Authors:  Mara Jana Broadhurst; John Daniel Kelly; Ann Miller; Amanda Semper; Daniel Bailey; Elisabetta Groppelli; Andrew Simpson; Tim Brooks; Susan Hula; Wilfred Nyoni; Alhaji B Sankoh; Santigi Kanu; Alhaji Jalloh; Quy Ton; Nicholas Sarchet; Peter George; Mark D Perkins; Betsy Wonderly; Megan Murray; Nira R Pollock
Journal:  Lancet       Date:  2015-06-25       Impact factor: 79.321

6.  Clinical illness and outcomes in patients with Ebola in Sierra Leone.

Authors:  John S Schieffelin; Jeffrey G Shaffer; Augustine Goba; Michael Gbakie; Stephen K Gire; Andres Colubri; Rachel S G Sealfon; Lansana Kanneh; Alex Moigboi; Mambu Momoh; Mohammed Fullah; Lina M Moses; Bethany L Brown; Kristian G Andersen; Sarah Winnicki; Stephen F Schaffner; Daniel J Park; Nathan L Yozwiak; Pan-Pan Jiang; David Kargbo; Simbirie Jalloh; Mbalu Fonnie; Vandi Sinnah; Issa French; Alice Kovoma; Fatima K Kamara; Veronica Tucker; Edwin Konuwa; Josephine Sellu; Ibrahim Mustapha; Momoh Foday; Mohamed Yillah; Franklyn Kanneh; Sidiki Saffa; James L B Massally; Matt L Boisen; Luis M Branco; Mohamed A Vandi; Donald S Grant; Christian Happi; Sahr M Gevao; Thomas E Fletcher; Robert A Fowler; Daniel G Bausch; Pardis C Sabeti; S Humarr Khan; Robert F Garry
Journal:  N Engl J Med       Date:  2014-10-29       Impact factor: 91.245

7.  Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor.

Authors:  Jeffrey E Lee; Marnie L Fusco; Ann J Hessell; Wendelien B Oswald; Dennis R Burton; Erica Ollmann Saphire
Journal:  Nature       Date:  2008-07-10       Impact factor: 49.962

8.  Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

Authors:  Emily P Thi; Chad E Mire; Amy C H Lee; Joan B Geisbert; Joy Z Zhou; Krystle N Agans; Nicholas M Snead; Daniel J Deer; Trisha R Barnard; Karla A Fenton; Ian MacLachlan; Thomas W Geisbert
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

9.  Reemergence of chikungunya virus in Bo, Sierra Leone.

Authors:  Rashid Ansumana; Kathryn H Jacobsen; Tomasz A Leski; Andrea L Covington; Umaru Bangura; Mary H Hodges; Baochuan Lin; Alfred S Bockarie; Joseph M Lamin; Moses J Bockarie; David A Stenger
Journal:  Emerg Infect Dis       Date:  2013-07       Impact factor: 6.883

10.  Prognostic Indicators for Ebola Patient Survival.

Authors:  Samuel J Crowe; Matthew J Maenner; Solomon Kuah; Bobbie Rae Erickson; Megan Coffee; Barbara Knust; John Klena; Joyce Foday; Darren Hertz; Veerle Hermans; Jay Achar; Grazia M Caleo; Michel Van Herp; César G Albariño; Brian Amman; Alison Jane Basile; Scott Bearden; Jessica A Belser; Eric Bergeron; Dianna Blau; Aaron C Brault; Shelley Campbell; Mike Flint; Aridth Gibbons; Christin Goodman; Laura McMullan; Christopher Paddock; Brandy Russell; Johanna S Salzer; Angela Sanchez; Tara Sealy; David Wang; Gbessay Saffa; Alhajie Turay; Stuart T Nichol; Jonathan S Towner
Journal:  Emerg Infect Dis       Date:  2016-02       Impact factor: 6.883

View more
  10 in total

Review 1.  Rapid diagnostic tests versus RT-PCR for Ebola virus infections: a systematic review and meta-analysis.

Authors:  Basilua Andre Muzembo; Kei Kitahara; Ayumu Ohno; Ngangu Patrick Ntontolo; Nlandu Roger Ngatu; Keinosuke Okamoto; Shin-Ichi Miyoshi
Journal:  Bull World Health Organ       Date:  2022-06-01       Impact factor: 13.831

2.  Analysis of CD8+ T cell response during the 2013-2016 Ebola epidemic in West Africa.

Authors:  Saori Sakabe; Brian M Sullivan; Jessica N Hartnett; Refugio Robles-Sikisaka; Karthik Gangavarapu; Beatrice Cubitt; Brian C Ware; Dylan Kotliar; Luis M Branco; Augustine Goba; Mambu Momoh; John Demby Sandi; Lansana Kanneh; Donald S Grant; Robert F Garry; Kristian G Andersen; Juan Carlos de la Torre; Pardis C Sabeti; John S Schieffelin; Michael B A Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-23       Impact factor: 11.205

Review 3.  Epidemiology and Management of the 2013-16 West African Ebola Outbreak.

Authors:  M L Boisen; J N Hartnett; A Goba; M A Vandi; D S Grant; J S Schieffelin; R F Garry; L M Branco
Journal:  Annu Rev Virol       Date:  2016-08-15       Impact factor: 10.431

4.  Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR.

Authors:  Cassio M Fontes; Barbara D Lipes; Jason Liu; Krystle N Agans; Aiwei Yan; Patricia Shi; Daniela F Cruz; Garrett Kelly; Kelli M Luginbuhl; Daniel Y Joh; Stephanie L Foster; Jacob Heggestad; Angus Hucknall; Maiken H Mikkelsen; Carl F Pieper; Roarke W Horstmeyer; Thomas W Geisbert; Michael D Gunn; Ashutosh Chilkoti
Journal:  Sci Transl Med       Date:  2021-04-07       Impact factor: 17.956

5.  Needle lost in the haystack: multiple reaction monitoring fails to detect Treponema pallidum candidate protein biomarkers in plasma and urine samples from individuals with syphilis.

Authors:  Geert A Van Raemdonck; Kara K Osbak; Xaveer Van Ostade; Chris R Kenyon
Journal:  F1000Res       Date:  2018-03-19

6.  Species-specific quantification of circulating ebolavirus burden using VP40-derived peptide variants.

Authors:  Qingbo Shu; Tara Kenny; Jia Fan; Christopher J Lyon; Lisa H Cazares; Tony Y Hu
Journal:  PLoS Pathog       Date:  2021-11-08       Impact factor: 6.823

7.  Development and validation of a pen side test for Rift Valley fever.

Authors:  Catherine Cêtre-Sossah; Aurélie Pédarrieu; Mikael Juremalm; Petrus Jansen Van Vuren; Alejandro Brun; Ahmed Bezeid Ould El Mamy; Jean-Michel Héraud; Claudia Filippone; Jean-Pierre Ravalohery; Hassan Chaabihi; Emmanuel Albina; Laure Dommergues; Janusz Paweska; Eric Cardinale
Journal:  PLoS Negl Trop Dis       Date:  2019-09-11

8.  Early detection of Ebola virus proteins in peripheral blood mononuclear cells from infected mice.

Authors:  Michael D Ward; Tara Kenny; Ernie Bruggeman; Christopher D Kane; Courtney L Morrell; Molly M Kane; Sandra Bixler; Sarah L Grady; Rachel S Quizon; Mekbib Astatke; Lisa H Cazares
Journal:  Clin Proteomics       Date:  2020-03-17       Impact factor: 3.988

9.  Characterization and analytical validation of a new antigenic rapid diagnostic test for Ebola virus disease detection.

Authors:  Céline Couturier; Atsuhiko Wada; Karen Louis; Maxime Mistretta; Benoit Beitz; Moriba Povogui; Maryline Ripaux; Charlotte Mignon; Bettina Werle; Adrien Lugari; Delphine Pannetier; Sabine Godard; Anne Bocquin; Stéphane Mely; Ismaël Béavogui; Jean Hébélamou; David Leuenberger; Philippe Leissner; Takeshi Yamamoto; Patrick Lécine; Christophe Védrine; Julie Chaix
Journal:  PLoS Negl Trop Dis       Date:  2020-01-17

10.  Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus.

Authors:  Haley L DeMers; Shihua He; Sujata G Pandit; Emily E Hannah; Zirui Zhang; Feihu Yan; Heather R Green; Denise F Reyes; Derrick Hau; Megan E McLarty; Louis Altamura; Cheryl Taylor-Howell; Marcellene A Gates-Hollingsworth; Xiangguo Qiu; David P AuCoin
Journal:  PLoS Negl Trop Dis       Date:  2020-11-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.